CellSource Co., Ltd. (TYO:4880)
Japan · Delayed Price · Currency is JPY 345.00
-11.00 (-3.09%)
Aug 27, 2026, 1:28 PM JST
CellSource Market Cap
CellSource has a market cap or net worth of 7.07 billion as of August 26, 2026. Its market cap has decreased by -43.02% in one year.
Market Cap
7.07B
Enterprise Value
2.28B
Revenue
3.67B
Ranking
n/a
PE Ratio
100.82
Stock Price
345.00
ChartMarket Cap Chart
Since October 29, 2019, CellSource's market cap has decreased from 13.48B to 7.07B, a decrease of -47.57%. That is a compound annual growth rate of -9.02%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 26, 2026 | 7.07B | -10.65% |
| Dec 30, 2025 | 7.91B | -52.01% |
| Dec 30, 2024 | 16.48B | -34.91% |
| Dec 29, 2023 | 25.32B | -66.16% |
| Dec 30, 2022 | 74.83B | -26.01% |
| Dec 30, 2021 | 101.14B | 51.52% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Oct 29, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| OncoTherapy Science | 8.57B |
| Carna Biosciences | 8.52B |
| StemCell Institute | 7.80B |
| BrightPath Biotherapeutics | 7.36B |
| MEDINET | 7.35B |
| ADR Biomedical Holdings | 6.82B |
| Chiome Bioscience | 6.63B |
| Chordia Therapeutics | 6.34B |